oxonic acid has been researched along with Minimal Disease, Residual in 11 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grade 3 neutropenia was common (35%)." | 6.90 | A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019) |
| "Grade 3 neutropenia was common (35%)." | 2.90 | A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019) |
| "It was unclear whether the transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for adenocarcinoma of the esophago-gastric (AEG) junction are as feasible and safe as D2 gastrectomy following NAC." | 2.82 | Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial. ( Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2016) |
| "The regrowth of an isolated local residual tumor without a distant metastasis was diagnosed 65 months after the resection." | 1.43 | [Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein]. ( Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E, 2016) |
| "The prognosis of unresectable gastric cancer is poor." | 1.42 | Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. ( Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, O, 2015) |
| "Medical records of 133 patients with extrahepatic cholangiocarcinoma who underwent curative resection were reviewed retrospectively." | 1.39 | Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. ( Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K, 2013) |
| "Patients with residual tumors after the initial treatment had a response rate of 47." | 1.36 | [Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment]. ( Katsuno, M; Sato, N; Sugio, Y; Tachibana, S; Tani, Y; Watanabe, N; Zusho, H, 2010) |
| " This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data." | 1.34 | Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007) |
| "was started for the residual cancer lesions, with CDDP i." | 1.32 | [Sustained NC status for a long period after combined chemotherapy of TS-1 and CDDP for residual lesions following gastrectomy for gastric cancer]. ( Hasegawa, S; Imazu, H; Matsubara, T; Nakamura, Y; Nozoe, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Motoi, F | 1 |
| Satoi, S | 1 |
| Honda, G | 1 |
| Wada, K | 1 |
| Shinchi, H | 1 |
| Matsumoto, I | 1 |
| Sho, M | 1 |
| Tsuchida, A | 1 |
| Unno, M | 1 |
| Murakami, Y | 1 |
| Uemura, K | 1 |
| Sudo, T | 1 |
| Hashimoto, Y | 1 |
| Kondo, N | 1 |
| Nakagawa, N | 1 |
| Muto, T | 1 |
| Sasaki, H | 1 |
| Urabe, K | 1 |
| Sueda, T | 1 |
| Kondo, J | 1 |
| Nisimura, T | 1 |
| Nagashima, Y | 1 |
| Okada, T | 1 |
| Nakamura, M | 1 |
| Setoguchi, M | 1 |
| Yoshino, S | 1 |
| Sakata, K | 1 |
| Okabayashi, T | 1 |
| Shima, Y | 1 |
| Iwata, J | 1 |
| Morita, S | 1 |
| Sumiyoshi, T | 1 |
| Kozuki, A | 1 |
| Tokumaru, T | 1 |
| Iiyama, T | 1 |
| Kosaki, T | 1 |
| Kobayashi, M | 1 |
| Hanazaki, K | 1 |
| Fukuchi, M | 1 |
| Ishiguro, T | 1 |
| Ogata, K | 1 |
| Suzuki, O | 1 |
| Kumagai, Y | 1 |
| Ishibashi, K | 1 |
| Ishida, H | 1 |
| Kuwano, H | 1 |
| Mochiki, E | 1 |
| Yoshikawa, T | 1 |
| Aoyama, T | 1 |
| Tanabe, K | 1 |
| Nishikawa, K | 1 |
| Ito, Y | 1 |
| Hayashi, T | 1 |
| Cho, H | 1 |
| Miyashita, Y | 1 |
| Tsuburaya, A | 1 |
| Sakamoto, J | 1 |
| Matsumura, T | 1 |
| Totsuka, E | 1 |
| Kitamura, K | 1 |
| Okada, K | 1 |
| Inose, S | 1 |
| Koyama, M | 1 |
| Nakamura, N | 1 |
| Masamura, S | 1 |
| Karikomi, K | 1 |
| Suwa, T | 1 |
| Katsuno, M | 1 |
| Watanabe, N | 1 |
| Sugio, Y | 1 |
| Tachibana, S | 1 |
| Tani, Y | 1 |
| Sato, N | 1 |
| Zusho, H | 1 |
| Sakai, W | 1 |
| Imazu, H | 1 |
| Yoshida, I | 1 |
| Tonomura, S | 1 |
| Nozoe, Y | 1 |
| Nakamura, Y | 1 |
| Hasegawa, S | 1 |
| Matsubara, T | 1 |
| Sakurai, Y | 1 |
| Ochiai, M | 1 |
| Takemura, M | 1 |
| Osugi, H | 1 |
| Lee, S | 1 |
| Taguchi, S | 1 |
| Kaneko, M | 1 |
| Tanaka, Y | 1 |
| Fukuhara, K | 1 |
| Fujiwara, Y | 1 |
| Nishizawa, S | 1 |
| Kinoshita, H | 1 |
| Yamanaka, T | 1 |
| Matsumoto, S | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Nagai, Y | 1 |
| Fukushima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for oxonic acid and Minimal Disease, Residual
| Article | Year |
|---|---|
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1 | 2019 |
Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2016 |
9 other studies available for oxonic acid and Minimal Disease, Residual
| Article | Year |
|---|---|
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
[A case of locally advanced residual gastric cancer treated with combined resection of multiple adjacent organs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hepatecto | 2013 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemo | 2014 |
Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; | 2016 |
[Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Head | 2010 |
[Sustained NC status for a long period after combined chemotherapy of TS-1 and CDDP for residual lesions following gastrectomy for gastric cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2003 |
[Remnant gastric cancer in which prolonged no change status was maintained with low-dose TS-1--a case report].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellul | 2003 |
Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Creatinine; D | 2007 |